Biotech

All Articles

Lykos will inquire FDA to reevaluate its own decision following denial of MDMA treatment for post-traumatic stress disorder

.Following a poor revealing for Lykos Therapeutics' MDMA prospect for trauma at a current FDA consul...

AN 2 halves head count, ceases phase 3 trial after records let down

.AN2 Therapies is re-thinking its service in response to dull midphase data, swearing to give up hal...

Merck pays $700M for bispecific, spying autoimmune position as well as odds to challenge Amgen in cancer

.Merck &amp Co. is actually paying for $700 thousand upfront to challenge Amgen in a blood cancer ma...

Gilead spends J&ampJ $320M to go out licensing bargain for seladelpar

.With Gilead Sciences almost an FDA selection for its liver health condition medication seladelpar, ...

' All palms on deck' at Lilly as peers target weight problems market

.Chief executive officer David Ricks can easily observe the companies setting up camping tents at ba...

Entero giving up workers, leaving office and pausing R&ampD

.Bed mattress Liquidators has switched Entero Rehabs white as a sheet. The collector purchased Enter...

Exelixis goes down ADC after deciding it's no suit for Tivdak

.Exelixis is actually giving up on its own cells element (TF)- targeting antibody-drug conjugate aft...

Relay loses interest in SHP2 prevention after Genentech leaves behind

.3 weeks after Roche's Genentech device walked away from an SHP2 inhibitor treaty, Relay Rehab has a...

Stoke's Dravet syndrome med released of partial medical hold

.Stoke Therapeutics' Dravet syndrome drug has actually been actually without a partial hold, removin...

Fierce Biotech's Gabrielle Masson provides Strong 15 at NYSE

.Intense Biotech Associate Publisher Gabrielle Masson offered the 2024 training class of Ferocious 1...